Despite inducing objective responses in ~50% of melanoma patients [8], monotherapy using BRAF inhibitors such as vemurafenib, dabrafenib and encorafenib only induce objective responses in ~5% of BRAFV600E metastatic CRCs [9]. This evidence concerns the gene BRAF and melanoma.